TY - JOUR
T1 - Combining Chemical Catalysis with Enzymatic Steps for the Synthesis of the Artemisinin Precursor Dihydroartemisinic Acid
AU - Upadhyay, Vikas
AU - Li, Hongxiang
AU - He, Jiachen
AU - Ocampo, Blake Edward
AU - Cook, Silas
AU - Zhao, Huimin
AU - Maranas, Costas D.
N1 - We thank Dr. Martin Burke (Molecule Maker Lab Institute (MMLI)) and Dr. Scott E. Denmark (MMLI) for the helpful discussions and for providing valuable inputs on the designed pathways for making decisions on replacing challenging enzymatic steps with chemical reactions and suggestions in the language improvement. This work is supported by the U.S. National Science Foundation funded Molecule Maker Lab Institute (MMLI), award number 2019897 supported by the National AI Research Institutes Program of the Directorate for Computer and Information Science and Engineering (CISE), in collaboration with the Division of Chemistry (CHE) and the Division of Chemical, Bioengineering, and Environmental Transport Systems (CBET) awarded to CDM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
PY - 2025/4/18
Y1 - 2025/4/18
N2 - The supply of artemisinin, the primary antimalarial drug recommended by the World Health Organization (WHO), is limited due to synthesis cost and supply constraints. This study explores novel chemo-enzymatic pathways for the efficient synthesis of dihydroartemisinic acid (DHAA), the penultimate precursor to artemisinin. The key concept here is to leverage the seamless integration of chemical and enzymatic steps for more thoroughly exploring synthesis alternatives. Using novoStoic, a biosynthetic pathway design tool, we identified previously unexplored carbon- and energy-balanced pathways for converting amorpha-4,11-diene (AMPD) to DHAA. For some of the enzymatically catalyzed steps lacking efficient enzymes, chemical catalysis alternatives were proposed and implemented, leading to a hybrid chemo-enzymatic pathway design. The proposed pathway converts AMPD directly to DHAA without going through artemisinic acid (AA), making it a shorter pathway compared with the existing synthesis routes for artemisinin. This effort paves the way for the systematic design of chemo-enzymatic pathways and provides insight into decision strategies between chemical synthesis and enzymatic synthesis steps. It serves as an example of how synthesis pathway design tools can be integrated with human intuition for accelerating retrosynthesis and how AI-based tools can identify and replace human intuitions to automate the decision processes. This can help reduce human-machine interventions and improve the development of future tools for synthesis planning.
AB - The supply of artemisinin, the primary antimalarial drug recommended by the World Health Organization (WHO), is limited due to synthesis cost and supply constraints. This study explores novel chemo-enzymatic pathways for the efficient synthesis of dihydroartemisinic acid (DHAA), the penultimate precursor to artemisinin. The key concept here is to leverage the seamless integration of chemical and enzymatic steps for more thoroughly exploring synthesis alternatives. Using novoStoic, a biosynthetic pathway design tool, we identified previously unexplored carbon- and energy-balanced pathways for converting amorpha-4,11-diene (AMPD) to DHAA. For some of the enzymatically catalyzed steps lacking efficient enzymes, chemical catalysis alternatives were proposed and implemented, leading to a hybrid chemo-enzymatic pathway design. The proposed pathway converts AMPD directly to DHAA without going through artemisinic acid (AA), making it a shorter pathway compared with the existing synthesis routes for artemisinin. This effort paves the way for the systematic design of chemo-enzymatic pathways and provides insight into decision strategies between chemical synthesis and enzymatic synthesis steps. It serves as an example of how synthesis pathway design tools can be integrated with human intuition for accelerating retrosynthesis and how AI-based tools can identify and replace human intuitions to automate the decision processes. This can help reduce human-machine interventions and improve the development of future tools for synthesis planning.
KW - antimalarial drug precursor
KW - artemisinin
KW - biosynthesis planning
KW - chemo-enzymatic synthesis
KW - dihydroartemisinic acid
UR - http://www.scopus.com/inward/record.url?scp=105000265734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105000265734&partnerID=8YFLogxK
U2 - 10.1021/acssynbio.4c00707
DO - 10.1021/acssynbio.4c00707
M3 - Article
C2 - 40105756
AN - SCOPUS:105000265734
SN - 2161-5063
VL - 14
SP - 1112
EP - 1120
JO - ACS synthetic biology
JF - ACS synthetic biology
IS - 4
ER -